
Bio-Techne (TECH) Stock Forecast & Price Target
Bio-Techne (TECH) Analyst Ratings
Bulls say
Bio-Techne has demonstrated robust financial performance, reporting a 9% organic growth in FQ2'25, which contributed to a revenue beat of approximately 4%, largely driven by increased spending in the pharmaceutical and biotech sectors. The company’s segmented growth was notable, with the Protein Sciences segment seeing an 8% year-over-year organic increase, while the Diagnostics and Spatial Biology segment experienced a 12% organic growth, reflecting strong demand across various applications. Furthermore, strategic shifts made under previous leadership and favorable market conditions are expected to support continued growth, positioning Bio-Techne favorably for consistent double-digit revenue growth and potential margin expansion in the future.
Bears say
Bio-Techne faces potential risks to its revenue and earnings estimates due to anticipated lower demand for its current and future product offerings, which could result in revenue declines particularly in the smaller biotech purchasing segment. The company is also experiencing elevated inventories and reduced equipment sales as a consequence of supply chain disruptions from the pandemic, compounded by a slowdown in growth comparable to larger industry competitors. Furthermore, prolonged macroeconomic challenges affecting end markets for life science tools and diagnostics, as well as increasing competition from larger firms, raise concerns about the company’s ability to meet future industry demand and achieve consistent revenue growth.
This aggregate rating is based on analysts' research of Bio-Techne and is not a guaranteed prediction by Public.com or investment advice.
Bio-Techne (TECH) Analyst Forecast & Price Prediction
Start investing in Bio-Techne (TECH)
Order type
Buy in
Order amount
Est. shares
0 shares